Trial Profile
A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary) ; Venlafaxine (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Proof of concept; Therapeutic Use
- 29 May 2020 Status changed from recruiting to discontinued.
- 18 Jun 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 18 Jun 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.